<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.4 20190208//EN"
       "JATS-journalpublishing1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="1.4" xml:lang="en">
 <front>
  <journal-meta>
   <journal-id journal-id-type="publisher-id">Tavricheskiy Mediko-Biologicheskiy Vestnik</journal-id>
   <journal-title-group>
    <journal-title xml:lang="en">Tavricheskiy Mediko-Biologicheskiy Vestnik</journal-title>
    <trans-title-group xml:lang="ru">
     <trans-title>Таврический медико-биологический вестник</trans-title>
    </trans-title-group>
   </journal-title-group>
   <issn publication-format="print">2070-8092</issn>
  </journal-meta>
  <article-meta>
   <article-id pub-id-type="publisher-id">53561</article-id>
   <article-id pub-id-type="doi">10.29039/2070-8092-2020-23-3-52-60</article-id>
   <article-categories>
    <subj-group subj-group-type="toc-heading" xml:lang="ru">
     <subject>Оригинальные статьи</subject>
    </subj-group>
    <subj-group subj-group-type="toc-heading" xml:lang="en">
     <subject>Original articles</subject>
    </subj-group>
    <subj-group>
     <subject>Оригинальные статьи</subject>
    </subj-group>
   </article-categories>
   <title-group>
    <article-title xml:lang="en">ALDOSTERONE BLOOD LEVEL INFLUENCE ON THE REMODELING OF HEART AND VESSELS IN PATIENTS WITH TYPE 2 DIABETES AND ARTERIAL HYPERTENSION</article-title>
    <trans-title-group xml:lang="ru">
     <trans-title>ВЛИЯНИЕ УРОВНЯ АЛЬДОСТЕРОНА КРОВИ НА РЕМОДЕЛИРОВАНИЕ СЕРДЦА И СОСУДОВ У БОЛЬНЫХ САХАРНЫМ ДИАБЕТОМ 2 ТИПА И АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИЕЙ</trans-title>
    </trans-title-group>
   </title-group>
   <contrib-group content-type="authors">
    <contrib contrib-type="author">
     <name-alternatives>
      <name xml:lang="ru">
       <surname>Крутиков</surname>
       <given-names>Евгений Сергеевич</given-names>
      </name>
      <name xml:lang="en">
       <surname>Krutikov</surname>
       <given-names>E. S.</given-names>
      </name>
     </name-alternatives>
     <xref ref-type="aff" rid="aff-1"/>
    </contrib>
    <contrib contrib-type="author">
     <name-alternatives>
      <name xml:lang="ru">
       <surname>Цветков</surname>
       <given-names>Владимир Александрович</given-names>
      </name>
      <name xml:lang="en">
       <surname>Tsvetkov</surname>
       <given-names>V. A.</given-names>
      </name>
     </name-alternatives>
     <xref ref-type="aff" rid="aff-1"/>
    </contrib>
    <contrib contrib-type="author">
     <name-alternatives>
      <name xml:lang="ru">
       <surname>Чистякова</surname>
       <given-names>Светлана Игоревна</given-names>
      </name>
      <name xml:lang="en">
       <surname>Chistyakova</surname>
       <given-names>Svetlana Igorevna</given-names>
      </name>
     </name-alternatives>
     <xref ref-type="aff" rid="aff-1"/>
    </contrib>
   </contrib-group>
   <aff-alternatives id="aff-1">
    <aff>
     <institution xml:lang="ru">Крымский Федеральный Университет им. В.И. Вернадского</institution>
     <country>RU</country>
    </aff>
    <aff>
     <institution xml:lang="en">V.I. Vernadsky Crimean Federal University</institution>
     <country>RU</country>
    </aff>
   </aff-alternatives>
   <pub-date publication-format="print" date-type="pub" iso-8601-date="2022-10-19T15:57:05+03:00">
    <day>19</day>
    <month>10</month>
    <year>2022</year>
   </pub-date>
   <pub-date publication-format="electronic" date-type="pub" iso-8601-date="2022-10-19T15:57:05+03:00">
    <day>19</day>
    <month>10</month>
    <year>2022</year>
   </pub-date>
   <volume>23</volume>
   <issue>3</issue>
   <fpage>52</fpage>
   <lpage>60</lpage>
   <history>
    <date date-type="received" iso-8601-date="2022-10-19T00:00:00+03:00">
     <day>19</day>
     <month>10</month>
     <year>2022</year>
    </date>
   </history>
   <self-uri xlink:href="https://ma.cfuv.ru/site/page/show/docid/260823">https://ma.cfuv.ru/site/page/show/docid/260823</self-uri>
   <abstract xml:lang="ru">
    <p>256  пациентам  определяли  уровень  альдостерона  крови,  проводили  суточное  мониторирование артериального давления (СМАД) и эходопплеркардиографию, изучали показатели жесткости артериальных сосудов.  У  больных  с  СД  2  типа  и  АГ  уровень  альдостерона  крови  составил  от  25  до  186  пг/  мл,  что соответствовало референсной норме. Пациенты с уровнем альдостерона менее 25-го процентиля составили 15 % обследованных – I группа; II группа – больные с средним уровнем альдостерона (25-75 процентили) – 46%; с уровнем  более  75-го  процентиля  –  39%,  были  включены  в  III  группу.  В  исследуемых  группах  офисное артериальное  давление  (АД)  не  зависело  от  уровня  альдостерона,  однако  у  пациентов  как  с  уровнем альдостерона  более  75-го  процентиля,  так  и  менее  25-го  процентиля  при  проведении  СМАД  было  выявлено повышение среднесуточного пульсового АД и недостаточная степень ночного снижения АД.  Аналогично, в I и III группах было выявлено статистически значимое увеличение показателей артериальной жесткости, по сравнению с лицами, имевшими средний уровень альдостерона. Нарушения диастолической функции и гипертрофия ЛЖ также были более выражены в группах пациентов с уровнем альдостерона  менее 25-го и более 75-го процентиля. Заключение. У пациентов с СД 2 типа уровень альдостерона крови менее 25-го и более 75-го процентиля в пределах  референсной  нормы  ассоциируется  с  большей  выраженностью  процессов  ремоделирования миокарда и артериальных сосудов.</p>
   </abstract>
   <trans-abstract xml:lang="en">
    <p>256 patients with type 2 diabetes and arterial hypertension (AH) were examined. The blood aldosterone level was determined in all patients, 24-hour blood pressure monitoring (BPM) and echodopplercardiography were performed, and the parameters of arterial vascular stiffness were studied. Results. In patients with type 2 diabetes and hypertension, the level of aldosterone in the blood ranged from 25 to 186 pg / ml, which corresponded to the reference norm. Patients with a level of aldosterone less than 25 percentile accounted for 15% of the examined - group I; Group II - patients with middle aldosterone levels (25-75 percentiles) - 46%; with a level more than 75 percentile - 39%, were included in group III. In the studied groups, office blood pressure (BP) did not depend on the level of aldosterone, however, in patients with both aldosterone levels above the 75th percentile and below the 25th percentile, an increase in the average daily pulse BP and an insufficient degree of nighttime BP reduction were revealed during BPM. Similarly, in groups I and III, there was a statistically significant increase in arterial stiffness indicators, compared with individuals with an average level of aldosterone. Disorders of diastolic function and LV hypertrophy were also more pronounced in groups of patients with aldosterone levels less than the 25th and more than 75th percentile. Conclusion. In patients with type 2 diabetes, the level of blood aldosterone less than the 25th and more than 75th percentile within the reference norm is associated with a greater severity of myocardial and arterial vessel remodeling processes.</p>
   </trans-abstract>
   <kwd-group xml:lang="ru">
    <kwd>альдостерон</kwd>
    <kwd>ремоделирование миокарда</kwd>
    <kwd>артериальная гипертензия</kwd>
    <kwd>сахарный  диабет 2 типа</kwd>
   </kwd-group>
   <kwd-group xml:lang="en">
    <kwd>aldosterone</kwd>
    <kwd>myocardial remodeling</kwd>
    <kwd>arterial hypertension</kwd>
    <kwd>type 2 diabetes</kwd>
   </kwd-group>
  </article-meta>
 </front>
 <body>
  <p></p>
 </body>
 <back>
  <ref-list>
   <ref id="B1">
    <label>1.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Mirabito  Colafella  K.  M,  Danser AHJ.  Recent  advances  in  angiotensin  research. Hypertension.  2017;69:994-999.  doi:0.1161/ HYPERTENSIONAHA.117.08931.</mixed-citation>
     <mixed-citation xml:lang="en">Mirabito  Colafella  K.  M,  Danser AHJ.  Recent  advances  in  angiotensin  research. Hypertension.  2017;69:994-999.  doi:0.1161/ HYPERTENSIONAHA.117.08931.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B2">
    <label>2.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Neves  M.  F.,  Cunha A. R.,  Cunha  M. R., Gismondi  R.  A.,  Oigman  W.  The  Role  of  Renin- Angiotensin-Aldosterone  System  and  Its  New Components in Arterial Stiffness and Vascular Aging. High Blood Pressure &amp; Cardiovascular Prevention. 2018;25:137-145. doi:10.1007/s40292-018-0252-5.</mixed-citation>
     <mixed-citation xml:lang="en">Neves  M.  F.,  Cunha A. R.,  Cunha  M. R., Gismondi  R.  A.,  Oigman  W.  The  Role  of  Renin- Angiotensin-Aldosterone  System  and  Its  New Components in Arterial Stiffness and Vascular Aging. High Blood Pressure &amp; Cardiovascular Prevention. 2018;25:137-145. doi:10.1007/s40292-018-0252-5.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B3">
    <label>3.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Aroor A. R., Demarco V. G., Jia G., Sun Z., Nistala R., Meininger G. A. The role of tissue renin- angiotensin-aldosterone system in the development of  endothelial  dysfunction  and  arterial  stiffness. Frontiers in endocrinology. 2013;4:161. doi: 10.3389/ fendo.2013.00161.</mixed-citation>
     <mixed-citation xml:lang="en">Aroor A. R., Demarco V. G., Jia G., Sun Z., Nistala R., Meininger G. A. The role of tissue renin- angiotensin-aldosterone system in the development of  endothelial  dysfunction  and  arterial  stiffness. Frontiers in endocrinology. 2013;4:161. doi: 10.3389/ fendo.2013.00161.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B4">
    <label>4.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Lother A., Hein L. Vascular mineralocorticoid receptors: linking risk factors, hypertension, and heart disease.  Hypertension.  2016;68:6-10.  doi:  10.1161/ HYPERTENSIONAHA.116.07418.</mixed-citation>
     <mixed-citation xml:lang="en">Lother A., Hein L. Vascular mineralocorticoid receptors: linking risk factors, hypertension, and heart disease.  Hypertension.  2016;68:6-10.  doi:  10.1161/ HYPERTENSIONAHA.116.07418.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B5">
    <label>5.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Briet M., Schiffrin E. L. Vascular actions of aldosterone. Journal of vascular research. 2013;50:89- 99. doi: 10.1159/000345243.</mixed-citation>
     <mixed-citation xml:lang="en">Briet M., Schiffrin E. L. Vascular actions of aldosterone. Journal of vascular research. 2013;50:89- 99. doi: 10.1159/000345243.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B6">
    <label>6.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Jia G, Aroor A R, Hill M A, Sowers J R. Role  of  Renin-Angiotensin-Aldosterone  System Activation in Promoting Cardiovascular Fibrosis and Stiffness. Hypertension. 2018;72:537-548. doi:10.1161/ HYPERTENSIONAHA.118.11065.</mixed-citation>
     <mixed-citation xml:lang="en">Jia G, Aroor A R, Hill M A, Sowers J R. Role  of  Renin-Angiotensin-Aldosterone  System Activation in Promoting Cardiovascular Fibrosis and Stiffness. Hypertension. 2018;72:537-548. doi:10.1161/ HYPERTENSIONAHA.118.11065.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B7">
    <label>7.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Solomon S. D., Claggett B., Lewis E. F., Desai A., Anand I., Sweitzer N. K.  Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. European Heart Journal. 2016;37 (5):455-62. doi: 10.1093/eurheartj/ehv464.</mixed-citation>
     <mixed-citation xml:lang="en">Solomon S. D., Claggett B., Lewis E. F., Desai A., Anand I., Sweitzer N. K.  Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. European Heart Journal. 2016;37 (5):455-62. doi: 10.1093/eurheartj/ehv464.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B8">
    <label>8.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Ribeiro-Oliveira A Jr, Nogueira A I, Pereira R M, Boas W W, Dos Santos R A, Simхes e Silva A C. The renin-angiotensin system and diabetes: An update. Vascular Health and Risk Management. 2008;4(4):787- 803. doi:10.2147/VHRM.S1905.</mixed-citation>
     <mixed-citation xml:lang="en">Ribeiro-Oliveira A Jr, Nogueira A I, Pereira R M, Boas W W, Dos Santos R A, Simhes e Silva A C. The renin-angiotensin system and diabetes: An update. Vascular Health and Risk Management. 2008;4(4):787- 803. doi:10.2147/VHRM.S1905.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B9">
    <label>9.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Griffin T. P., Wall D., Browne G. A., Dennedy M. C., O’Shea P. M. Associations between glycaemic control and  activation  of  the  renin-angiotensin-aldosterone system in participants with type 2 diabetes mellitus and  hypertension.  Annals  of  clinical  biochemistry. 2018;55(3):373-84. doi:10.1177/0004563217728964.</mixed-citation>
     <mixed-citation xml:lang="en">Griffin T. P., Wall D., Browne G. A., Dennedy M. C., O’Shea P. M. Associations between glycaemic control and  activation  of  the  renin-angiotensin-aldosterone system in participants with type 2 diabetes mellitus and  hypertension.  Annals  of  clinical  biochemistry. 2018;55(3):373-84. doi:10.1177/0004563217728964.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B10">
    <label>10.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Price D. A., Porter L. E., Gordon M., Fisher NDL, De`Oliveira JMF, Laffel LMB. The Paradox of  the  Low-Renin  State  in  Diabetic  Nephropathy. Journal  Of The American  Society  Of  Nephrology. 1999;10(11):2382-2391. ISSN: 1046-6673.</mixed-citation>
     <mixed-citation xml:lang="en">Price D. A., Porter L. E., Gordon M., Fisher NDL, De`Oliveira JMF, Laffel LMB. The Paradox of  the  Low-Renin  State  in  Diabetic  Nephropathy. Journal  Of The American  Society  Of  Nephrology. 1999;10(11):2382-2391. ISSN: 1046-6673.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B11">
    <label>11.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Pitt B., Williams G., Remme W., Martinez F., Lopez-Sendon J., Zannad F.  The EPHESUS Trial:Eplerenone  in  Patients  with  Heart  Failure  Due  to Systolic Dysfunction Complicating Acute Myocardial Infarction.  Cardiovascular  Drugs  and  Therapy. 2001;15:79-87. doi: 10.1023/A:1011119003788.</mixed-citation>
     <mixed-citation xml:lang="en">Pitt B., Williams G., Remme W., Martinez F., Lopez-Sendon J., Zannad F.  The EPHESUS Trial:Eplerenone  in  Patients  with  Heart  Failure  Due  to Systolic Dysfunction Complicating Acute Myocardial Infarction.  Cardiovascular  Drugs  and  Therapy. 2001;15:79-87. doi: 10.1023/A:1011119003788.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B12">
    <label>12.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Pitt B. ACE inhibitor co-therapy in patients with  heart  failure:  Rationale  for  the  Randomized Aldactone Evaluation Study (RALES). European Heart Journal.  1995;16(1):107-110.  doi:  10.1093/eurheartj/16. suppl_N.107.</mixed-citation>
     <mixed-citation xml:lang="en">Pitt B. ACE inhibitor co-therapy in patients with  heart  failure:  Rationale  for  the  Randomized Aldactone Evaluation Study (RALES). European Heart Journal.  1995;16(1):107-110.  doi:  10.1093/eurheartj/16. suppl_N.107.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B13">
    <label>13.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Дедов И. И., Шестакова М. В., Майоров А. Ю., Шамхалова М. Ш., Никонова Т. В., Сухарева О. Ю.  Алгоритмы  специализированной  медицинской помощи  больным  сахарным  диабетом.  Сахарный диабет. 2019;22(S.1):1-121. doi: 10.14341/DM221S1.</mixed-citation>
     <mixed-citation xml:lang="en">Dedov I. I., Shestakova M. V., Mayorov A. Yu., Shamhalova M. Sh., Nikonova T. V., Suhareva O. Yu.  Algoritmy  specializirovannoy  medicinskoy pomoschi  bol'nym  saharnym  diabetom.  Saharnyy diabet. 2019;22(S.1):1-121. doi: 10.14341/DM221S1.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B14">
    <label>14.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Кобалава Ж. Д., Конради А. О., Недогода С. В., Шляхто Е. В., Арутюнов Г. П., Баранова Е. И. Артериальная  гипертензия  у  взрослых.  Клинические рекомендации 2020. Российский кардиологический журнал.  2020;25(3):37-86.  doi:10.15829/1560-4071- 2020-3-3786.</mixed-citation>
     <mixed-citation xml:lang="en">Kobalava Zh. D., Konradi A. O., Nedogoda S. V., Shlyahto E. V., Arutyunov G. P., Baranova E. I. Arterial'naya  gipertenziya  u  vzroslyh.  Klinicheskie rekomendacii 2020. Rossiyskiy kardiologicheskiy zhurnal.  2020;25(3):37-86.  doi:10.15829/1560-4071- 2020-3-3786.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B15">
    <label>15.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Chobanian A. V., Bakris G. L., Black H. R., Cushman W. C., Green L. A., Izzo Jr. JL et al. The seventh report of the joint national committee on prevention, detection,  evaluation,  and  treatment  of  high  blood pressure: the JNC 7 report. Jama. 2003;289(19):2560- 71. doi:10.1001/jama.289.19.2560.</mixed-citation>
     <mixed-citation xml:lang="en">Chobanian A. V., Bakris G. L., Black H. R., Cushman W. C., Green L. A., Izzo Jr. JL et al. The seventh report of the joint national committee on prevention, detection,  evaluation,  and  treatment  of  high  blood pressure: the JNC 7 report. Jama. 2003;289(19):2560- 71. doi:10.1001/jama.289.19.2560.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B16">
    <label>16.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Lang R. M., Badano L. P., Mor-Avi V., Afilalo J., Armstrong A.,  Ernande L. Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular  Imaging,  European Heart Journal  - Cardiovascular  Imaging.  2015;16(30):233-271.  doi: 10.1093/ehjci/jev014.</mixed-citation>
     <mixed-citation xml:lang="en">Lang R. M., Badano L. P., Mor-Avi V., Afilalo J., Armstrong A.,  Ernande L. Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular  Imaging,  European Heart Journal  - Cardiovascular  Imaging.  2015;16(30):233-271.  doi: 10.1093/ehjci/jev014.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B17">
    <label>17.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Vlachopoulos C., Aznaouridis K., Stefanadis C. Prediction of cardiovascular events and all-cause mortality  with arterial  stiffness: a systematic review and meta-analysis. Journal of the American College of  Cardiology.  2010;55:1318-1327.  doi:  10.1016/j. jacc.2009.10.061.</mixed-citation>
     <mixed-citation xml:lang="en">Vlachopoulos C., Aznaouridis K., Stefanadis C. Prediction of cardiovascular events and all-cause mortality  with arterial  stiffness: a systematic review and meta-analysis. Journal of the American College of  Cardiology.  2010;55:1318-1327.  doi:  10.1016/j. jacc.2009.10.061.</mixed-citation>
    </citation-alternatives>
   </ref>
  </ref-list>
 </back>
</article>
